Cargando…

The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) refers to a very wide clinical spectrum. Advanced fibrosis that accompanies disease leads to the development of cirrhosis and hepatocellular carcinoma. Thus, identification of patients with advanced fibrosis is essential. The aim of the present s...

Descripción completa

Detalles Bibliográficos
Autores principales: Cichoż-Lach, Halina, Celiński, Krzysztof, Prozorow-Król, Beata, Swatek, Jarosław, Słomka, Maria, Lach, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560810/
https://www.ncbi.nlm.nih.gov/pubmed/23197236
http://dx.doi.org/10.12659/MSM.883601
_version_ 1782257864576860160
author Cichoż-Lach, Halina
Celiński, Krzysztof
Prozorow-Król, Beata
Swatek, Jarosław
Słomka, Maria
Lach, Tomasz
author_facet Cichoż-Lach, Halina
Celiński, Krzysztof
Prozorow-Król, Beata
Swatek, Jarosław
Słomka, Maria
Lach, Tomasz
author_sort Cichoż-Lach, Halina
collection PubMed
description BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) refers to a very wide clinical spectrum. Advanced fibrosis that accompanies disease leads to the development of cirrhosis and hepatocellular carcinoma. Thus, identification of patients with advanced fibrosis is essential. The aim of the present study was to compare the usefulness of NAFLD fibrosis and BARD scores in predicting fibrosis in NAFLD and to determine the risk factors of advanced fibrosis. MATERIAL/METHODS: The study included 126 patients with NAFLD. Fibrosis in liver biopsy was scored on a 5-point scale. The BARD and the NAFLD fibrosis scores were compared with the biopsy findings. RESULTS: Liver biopsy revealed 27 patients with advanced and 99 with mild/moderate fibrosis. Advanced fibrosis was statistically significantly more common in older patients with obesity, AST/ALT ratio ≥0.8, diabetes mellitus, and thrombocytes ≤200×10(3)/L. Positive predictive value, negative predictive value and AUROC curve for BARD score, and NAFLD fibrosis score were 68.57%, 96.70%, 0.865 and 70.59%, 98.11%, 0.919, respectively. CONCLUSIONS: Both scores are capable of ruling out advanced fibrosis and markedly reducing the need for liver biopsies in patients with NAFLD. Obesity, diabetes mellitus, thrombocytes ≤200×10(3)/L, advanced age and AST/ALT ratio ≥0.8 are the risk factors of advanced fibrosis.
format Online
Article
Text
id pubmed-3560810
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-35608102013-04-24 The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease Cichoż-Lach, Halina Celiński, Krzysztof Prozorow-Król, Beata Swatek, Jarosław Słomka, Maria Lach, Tomasz Med Sci Monit Clinical Research BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) refers to a very wide clinical spectrum. Advanced fibrosis that accompanies disease leads to the development of cirrhosis and hepatocellular carcinoma. Thus, identification of patients with advanced fibrosis is essential. The aim of the present study was to compare the usefulness of NAFLD fibrosis and BARD scores in predicting fibrosis in NAFLD and to determine the risk factors of advanced fibrosis. MATERIAL/METHODS: The study included 126 patients with NAFLD. Fibrosis in liver biopsy was scored on a 5-point scale. The BARD and the NAFLD fibrosis scores were compared with the biopsy findings. RESULTS: Liver biopsy revealed 27 patients with advanced and 99 with mild/moderate fibrosis. Advanced fibrosis was statistically significantly more common in older patients with obesity, AST/ALT ratio ≥0.8, diabetes mellitus, and thrombocytes ≤200×10(3)/L. Positive predictive value, negative predictive value and AUROC curve for BARD score, and NAFLD fibrosis score were 68.57%, 96.70%, 0.865 and 70.59%, 98.11%, 0.919, respectively. CONCLUSIONS: Both scores are capable of ruling out advanced fibrosis and markedly reducing the need for liver biopsies in patients with NAFLD. Obesity, diabetes mellitus, thrombocytes ≤200×10(3)/L, advanced age and AST/ALT ratio ≥0.8 are the risk factors of advanced fibrosis. International Scientific Literature, Inc. 2012-12-01 /pmc/articles/PMC3560810/ /pubmed/23197236 http://dx.doi.org/10.12659/MSM.883601 Text en © Med Sci Monit, 2011 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
spellingShingle Clinical Research
Cichoż-Lach, Halina
Celiński, Krzysztof
Prozorow-Król, Beata
Swatek, Jarosław
Słomka, Maria
Lach, Tomasz
The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease
title The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease
title_full The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease
title_fullStr The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease
title_full_unstemmed The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease
title_short The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease
title_sort bard score and the nafld fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3560810/
https://www.ncbi.nlm.nih.gov/pubmed/23197236
http://dx.doi.org/10.12659/MSM.883601
work_keys_str_mv AT cichozlachhalina thebardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease
AT celinskikrzysztof thebardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease
AT prozorowkrolbeata thebardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease
AT swatekjarosław thebardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease
AT słomkamaria thebardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease
AT lachtomasz thebardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease
AT cichozlachhalina bardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease
AT celinskikrzysztof bardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease
AT prozorowkrolbeata bardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease
AT swatekjarosław bardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease
AT słomkamaria bardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease
AT lachtomasz bardscoreandthenafldfibrosisscoreintheassessmentofadvancedliverfibrosisinnonalcoholicfattyliverdisease